Hydroxyzine Orifarm

Hydroxyzine Hydrochloride, the active ingredient in Hydroxyzine Orifarm, is a first‑generation antihistamine presented as an oral tablet for oral administration. It acts on peripheral H1 receptors and is employed to relieve allergic skin conditions, pruritus, anxiety, sedation and nausea in adult patients, providing both antihistaminic and calming effects.

GNH USA supplies Hydroxyzine Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels and ensuring quality compliance with EU standards.

Hydroxyzine Orifarm is a first‑generation antihistamine that blocks H1 receptors, reducing allergic and related symptoms.

Allergic skin conditions: reduces redness, swelling and itching associated with urticaria and other dermal allergies. Pruritus: alleviates intense itching caused by dermatologic or systemic conditions. Anxiety: provides mild sedation that can help manage short‑term anxiety episodes. Sedation: induces calming effects useful before medical procedures or for sleep support. Nausea: helps control nausea and vomiting related to allergic reactions or motion sickness.

Hydroxyzine Orifarm may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation leading to a dry sensation. - Dizziness: light‑headed feeling, especially when standing quickly. - Blurred vision: temporary visual disturbances. - Constipation: slowed gastrointestinal motility. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, swelling, or anaphylaxis. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

When prescribing Hydroxyzine Orifarm, clinicians should observe several precautions to ensure safe use. - Pregnancy: use only if potential benefit justifies the risk, as safety data are limited. - Elderly patients: start with lower doses and monitor for increased sedation and falls. - Concomitant CNS depressants: avoid excessive drowsiness by limiting combined use. - Driving and machinery: advise patients not to operate vehicles or heavy equipment until they know how the drug affects them. - Pre‑existing cardiac disease: monitor heart rhythm and blood pressure during therapy. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Hydroxyzine Orifarm can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Alcohol: combined use may cause profound sedation and respiratory depression. - Opioids or other CNS depressants: risk of excessive drowsiness, respiratory depression, and impaired coordination. - Anticholinergic agents: additive anticholinergic effects may lead to severe dry mouth, constipation, or urinary retention.

Moderate Interactions (Monitor Closely): - Other antihistamines: may increase sedation and anticholinergic burden. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): can raise hydroxyzine plasma levels, requiring dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce hydroxyzine effectiveness.